Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010478 | PMC |
| http://dx.doi.org/10.1093/geronb/gbac181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Alzheimer's disease (AD) remains a major neurocognitive disorder of global health significance. Globalizing ancestral diversity in AD genetics is essential to identify causal variants, improve diagnosis, and enable equitable therapeutic interventions across populations. The Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP) initiative addresses this by including African ancestry and Hispanic/Latinx (HL) ancestry populations.
View Article and Find Full Text PDFAssociation between Trust of Researchers and Willingness to Participate in Alzheimer's Disease Biomarker Research.
Alzheimers Dement Behav Socioecon Aging
September 2025
Indiana Alzheimer's Disease Research Center, 355 W. 16th Street Indianapolis, Indiana, 46202 USA.
Introduction: The study examined the relationship between trust of researchers in research naïve participants, including those at higher risk, and interest in Alzheimer's disease and related dementia (ADRD) biomarker research participation.
Methods: A cohort of 399 community-dwelling older adults completed a survey about their trust of researchers and interest in participating in ADRD biomarker research.
Results: After controlling for sociodemographics and knowledge of ADRD, higher trust of researchers was associated with lower levels of hesitancy to participate in ADRD biomarker and neuroimaging studies ( < 0.
Epigenetic clocks and longitudinal plasma biomarkers of Alzheimer's disease.
medRxiv
August 2025
Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA.
Introduction: Chronological age is the strongest risk factor for Alzheimer's disease and related dementias (ADRD). However, the association of accelerated biological aging relative to chronological age with ADRD pathology is unclear.
Methods: In a cohort of 2,366 cognitively unimpaired older women from the Women's Health Initiative Memory Study, we examined associations of five baseline measures of epigenetic age acceleration (EAA) with 15-year changes in plasma ADRD biomarkers.
The burden of cognitive impairment.
Alzheimers Dement
August 2025
Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California, USA.
Introduction: Over 10% of older American adults (age ≥ 65) experience cognitive impairment (CI) from Alzheimer's disease and related dementias (ADRD). An additional 15%-22% experience mild cognitive impairment (MCI), often preceding ADRD and in earlier life. However, CI burden estimates including MCI and early-onset CI (age < 65), remain limited.
View Article and Find Full Text PDFGuided by the community: Insights on recruitment science from the African Americans Fighting Alzheimer's in Midlife (AA-FAIM) Project.
Alzheimers Dement Behav Socioecon Aging
June 2025
Wisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, USA.
Introduction: Although Alzheimer's disease and related dementias (ADRDs) are disproportionately high in Black/African American (AA) individuals, this population is under-included in biomarker studies and clinical trials. This underrepresentation contributes to health disparities in treatment and disease outcomes. The Wisconsin Alzheimer's Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer's Prevention (WRAP) at the University of Wisconsin-Madison have been successfully conducting the African Americans Fighting Alzheimer's in Midlife (AA-FAIM) Project since 2016.
View Article and Find Full Text PDF